- Home
- XBP vs IFRX Comparison
XBP vs IFRX Comparison
Compare XBP & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XBP | IFRX |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.7M | 86.0M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | XBP | IFRX |
|---|---|---|
| Price | $0.67 | $0.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.80 |
| AVG Volume (30 Days) | 222.9K | ★ 7.6M |
| Earning Date | 11-14-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $62,823,000.00 | $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,216.24 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.42 | $0.71 |
| 52 Week High | $2.56 | $2.82 |
Technical Indicators
Market Signals| Indicator | XBP | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.48 | 39.78 |
| Support Level | $0.55 | $1.15 |
| Resistance Level | $0.72 | $1.28 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 68.19 | 1.21 |
Price Performance
Historical ComparisonAbout XBP XBP Europe Holdings Inc.
XBP Global Holdings Inc is a multinational leader in business process automation, serving over 2,500 clients-including more than 30 Fortune 100 companies. Its proprietary software and deep domain expertise position it as a trusted technology and services partner. With cloud-based solutions and a global footprint, XBP Global delivers measurable value, improves advances digital transformation, improves market-wide liquidity by expediting payments, and promotes sustainable business practices.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.